Free Trial
LON:SAR

Sareum (SAR) Share Price, News & Analysis

GBX 32
+0.50 (+1.59%)
(As of 07/26/2024 ET)
Today's Range
31.11
33
50-Day Range
30.75
45.20
52-Week Range
10
109.90
Volume
146,816 shs
Average Volume
931,995 shs
Market Capitalization
£34.54 million
P/E Ratio
N/A
Dividend Yield
1.10%
Price Target
N/A
SAR stock logo

About Sareum Stock (LON:SAR)

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancerandcancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.

SAR Stock Price History

SAR Stock News Headlines

Issue of RiverFort Subscription Shares
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Sareum Holdings PLC SAR
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Sareum Holdings plc (LON:SAR): Are Analysts Optimistic?
Sareum Holdings PLC (RYH0.SG)
Sareum surges as partner agrees licence for promising molecule
Sareum shares just jumped 22%! Here’s why
See More Headlines
Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Financial Services
CIK
N/A
Fax
N/A
Employees
3,211
Year Founded
N/A

Profitability

Net Income
£-4,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£47,204.00
Cash Flow
GBX 2.77 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£33.82 million
Optionable
Not Optionable
Beta
-1.03
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Timothy John Mitchell Ph.D. (Age 64)
    Founder, CEO & Executive Director
    Comp: $207.85k
  • Dr. John Charles Reader Ph.D. (Age 57)
    Founder, Chief Scientific Officer & Executive Director
    Comp: $205.8k
  • Mr. Clive H. W. Birch F.C.A. (Age 70)
    Senior Independent Non-Executive Director & Secretary
    Comp: $25k
  • Alexandra Harrison
    Head of IR

SAR Stock Analysis - Frequently Asked Questions

How have SAR shares performed this year?

Sareum's stock was trading at GBX 59.50 at the beginning of 2024. Since then, SAR shares have decreased by 46.2% and is now trading at GBX 32.
View the best growth stocks for 2024 here
.

How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Sareum own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Madagascar Oil (MOIL).

This page (LON:SAR) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners